Clinical Trial Update: Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the combination of 177Lu-TLX250 and Peposertib in CAIX-expressing solid tumors; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma
• Solid Tumor

Drugs mentioned

• 177Lu-TLX250 (TLX250)
• Peposertib (Peposertib)

Snippet

Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited | Conditions: Solid Tumor, Adult, Advanced Solid Tumor | Phase 1 | Status: RECRUITING